|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
FDA vs. Drug Ads: Cut the Kids and Dogs, Spell Out Side Effects
|
Arlene Weintraub |
02/06/12 |
National
|
|
Clarus Ventures Adjusts to Unpredictable Biotech World
|
Luke Timmerman |
01/20/12 |
Boston
|
|
Onyx, Bayer’s Next Cancer Drug Shows Slim Survival Edge
|
Luke Timmerman |
01/17/12 |
San Francisco
|
|
Civitas Charts Positive Data on Inhaled Parkinson’s Drug
|
Arlene Weintraub |
01/06/12 |
Boston
|
|
The Year in Seattle Biotech: Lots of Acquisitions, Few New Startups
|
Luke Timmerman |
12/22/11 |
Seattle
|
|
Buyouts, Quantified Health, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
12/01/11 |
San Diego
|
|
Idera Regains Cancer Drug Rights From Germany’s Merck; Stock Climbs
|
Luke Timmerman |
11/30/11 |
Boston
|
|
Alkermes Spinoff, Civitas, Gets Michael J. Fox Support for Inhalable Parkinson’s Drug
|
Luke Timmerman |
11/29/11 |
Boston
|
|
Eli Lilly CEO John Lechleiter on Tackling the Pharmaceutical R&D Crisis (Part 2)
|
Luke Timmerman |
11/22/11 |
National
|
|
Eli Lilly CEO John Lechleiter on Tackling the Pharmaceutical R&D Crisis (Part 1)
|
Luke Timmerman |
11/21/11 |
National
|
|
Aileron Expands Roche Deal, Agios Gets $78M, Genzyme MS Drug Advances, & More Boston-Area Life Sciences News
|
Erin Kutz |
11/18/11 |
Boston
|
|
Eli Lilly Pumps $4M into IDRI to Continue Hunt for TB Drugs
|
Luke Timmerman |
11/17/11 |
Seattle
|
|
Best Buy Picks Up MindShift, Termeer Funds NanoString, Basho Adds $5M More, & More Boston-Area Deals News
|
Erin Kutz |
11/09/11 |
Boston
|
|
Amylin and Eli Lilly Part Ways on Diabetes Drug; Alkermes Deal Intact
|
Bruce V. Bigelow |
11/08/11 |
San Diego
|
|
Deals Inked for Basho, Innocentive
|
Erin Kutz |
11/03/11 |
Boston
|
|
Xconomist of the Week: Pfizer’s Barbara Dalton to Speak at Our NY Life Sciences 2031 Forum
|
Arlene Weintraub |
09/29/11 |
New York
|
|
Ambrx Grabs $24M Upfront in New Diabetes, Heart Failure Research Deal With Bristol-Myers
|
Luke Timmerman |
09/22/11 |
San Diego
|
|
Adimab Inks Collaboration Deals with Biogen Idec, Novo Nordisk
|
Erin Kutz |
08/29/11 |
Boston
|
|
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies
|
Luke Timmerman |
08/29/11 |
Seattle
|
|
Seattle Genetics’ Market Debut, Pathway Gets Bought, Theraclone’s Latest Trick Against HIV, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
08/25/11 |
Seattle
|
|
Dendreon Adds Ex-ImClone CEO to Board
|
Luke Timmerman |
08/22/11 |
Seattle
|
|
T2 Nabs $23M, Ironwood Seeks IBS Drug Approval, FDA Sets Deadline for Alkermes Drug, & More Boston-Area Life Sciences News
|
Erin Kutz |
08/12/11 |
Boston
|
|
Adventrx Shares Plummet, Pfizer Adds UC San Diego to its Network, New RNAi Center Opens, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
08/11/11 |
San Diego
|
|
Bydureon FDA Deadline Set
|
Luke Timmerman |
08/10/11 |
San Diego
|
|
Amylin & Takeda Halt Obesity Drug Development
|
Bruce V. Bigelow |
08/04/11 |
San Diego
|
|
Vertex Sales Much Bigger Than Expected, Amylin Re-Submits Exenatide, Mini VC Fund Debuts, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
08/04/11 |
San Diego
|
|
Stéphane Bancel, Former bioMérieux CEO, Talks Future of Startups, Diagnostics, Pharma
|
Gregory T. Huang |
08/04/11 |
Boston
|
|
Biogen Gets Euro Approval, BSX Shows Solid Q2, Alkermes Tries Again, & More Boston-Area Life Sciences News
|
Erin Kutz |
07/29/11 |
Boston
|
|
Bydureon Sent Back to FDA
|
Luke Timmerman |
07/28/11 |
San Diego
|
|
Trius and Bayer Sign Deal, Brooks Buys Nexus Biosystems, Wildcat Discovery Gets $7.5M Financing, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
07/28/11 |
San Diego
|
|
Page 1 of
8 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
